LL-37 — a human cathelicidin peptide studied for antimicrobial defense, immune modulation, and tissue regeneration.
Also known as: Cathelicidin, ll37
LL-37 is the only cathelicidin-derived antimicrobial peptide produced by the human body. It's a 37-amino-acid fragment cleaved from a larger precursor protein called hCAP-18, and it's expressed almost everywhere — by epithelial cells lining the gut and airways, by neutrophils responding to infection, by skin keratinocytes, and by lymphocytes. It sits at the front line of innate immunity, the body's first-response defense system.
What makes LL-37 unusual among peptides is its dual personality. On one hand, it's a direct antimicrobial: it punches holes in bacterial membranes, disrupts viral envelopes, and breaks down biofilms. On the other hand, it's a sophisticated immune signaling molecule that recruits immune cells, shapes inflammatory responses, and promotes wound repair and new blood vessel formation. The same short peptide that kills pathogens also tells the body how to heal afterward.
Research interest in LL-37 has grown sharply alongside concerns about antibiotic resistance, but its potential extends well beyond infection. It's now being studied across cardiovascular disease, autoimmunity, oral health, bone regeneration, and chronic wounds — anywhere innate immunity and tissue repair intersect.
1 vendor carries LL-37.
Compare prices →Antimicrobial action is the most thoroughly characterized aspect of LL-37. A comprehensive 2025 review catalogued documented activity against more than 38 bacterial species, 16 fungi, and 16 viruses (1). The mechanisms are diverse: LL-37 inserts into and permeabilizes microbial membranes, generates oxidative stress inside pathogens, disrupts viral envelopes and entry, and interferes with replication machinery (1, 10).
A second front of antimicrobial action involves biofilms — the protective communities bacteria build to shield themselves from antibiotics and immune attack. Biofilms are responsible for many of the most stubborn chronic infections in medicine. A 2023 in-depth review found that LL-37 inhibits biofilm formation by a wide range of pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii (3). It works by blocking bacterial adhesion to surfaces, suppressing quorum-sensing (the chemical communication bacteria use to coordinate biofilm building), degrading the matrix that holds biofilms together, and downregulating the genes bacteria need to assemble them.
This breadth — bacteria, fungi, viruses, and biofilms through partly overlapping mechanisms — is why LL-37 has become a reference molecule in the search for next-generation antimicrobials, particularly against multidrug-resistant pathogens (1).
LL-37 functions as more than an antibiotic. It's classified as both a defensin (direct pathogen killer) and an alarmin — a molecule that alerts and recruits the immune system to a site of damage or infection (5). It attracts neutrophils, monocytes, and T cells through chemotactic signaling, modulates the activity of cytokines, and influences the release of neutrophil extracellular traps (NETs), a defense mechanism in which neutrophils expel webs of DNA to capture pathogens (5).
The structural basis for this versatility appears to be LL-37's amphipathic flexibility — it can adopt different shapes depending on its environment, allowing it to interact with bacterial membranes, human cell receptors, or DNA depending on context (5). Specific fragments of LL-37 (SK-24, IV-20, FK-13) have been identified as carrying distinct immunomodulatory activities, suggesting the parent peptide is essentially a toolkit of overlapping functions packaged into one sequence (4).
This immune-shaping role has a darker side worth understanding. In systemic lupus erythematosus, LL-37 forms complexes with DNA released from dying cells, and these complexes activate plasmacytoid dendritic cells through TLR9, driving the type I interferon production that fuels lupus autoimmunity (9). LL-37 and antibodies against it have been proposed as biomarkers for disease activity. The same property that makes LL-37 a powerful innate-immunity activator is what creates this risk in autoimmune-prone settings.
Beyond fighting infection, LL-37 appears to actively promote tissue repair. A 2022 review focused on bone and periodontal regeneration described LL-37 as inducing neovascularization — the growth of new blood vessels — and stimulating expression of VEGF, the master signaling molecule that drives angiogenesis (6). It also promotes the migration and differentiation of mesenchymal stem cells, the precursor cells responsible for rebuilding bone, cartilage, and connective tissue.
These activities translate into concrete repair effects: enhanced wound healing, improved angiogenesis, modulated apoptosis (controlled cell death), and supported tissue regeneration in the oral cavity, periodontium, and bone (6, 7). LL-37 expression in oral tissues appears to be a marker of healthy homeostasis, and disruption of its levels is associated with periodontitis, oral infections, and poor healing outcomes (7).
In the cardiovascular system, LL-37 has been examined for roles in atherosclerosis, thrombosis, inflammatory responses within blood vessels, and cardiac hypertrophy (2). Engineered analogs of LL-37 are being developed specifically to harness these regenerative and anti-inflammatory properties while minimizing unwanted effects.
LL-37's activity against enveloped viruses has drawn particular interest, with HIV being the most studied example. The peptide has been shown to inhibit HIV infection in primary T cells and to suppress key viral enzymes involved in replication (8). Its effects on HIV are complex — its immunomodulatory properties may both enhance and inhibit viral replication depending on context — but the direct antiviral activity has been consistent enough to position LL-37 as a candidate for prevention strategies.
What makes LL-37 especially intriguing as a prevention tool is the combination of activities it brings to a single molecule: direct anti-HIV activity, broad action against other sexually transmitted pathogens, and spermicidal effects. This profile has led researchers to evaluate LL-37 as a multipurpose prevention candidate — one compound that could simultaneously address multiple risks (8). Further work on stable analogs and delivery methods is needed before clinical translation, but the underlying biology supports continued investigation.
Reported issues with LL-37 in the published research center on two practical limitations: the peptide is broken down quickly by proteases in the body, and at high concentrations it can become toxic to host cells as well as pathogens (1). These properties have driven much of the work toward stable analogs and targeted delivery systems rather than direct use of native LL-37.
A more nuanced concern is LL-37's role in autoimmunity. Because it can form complexes with DNA that activate immune sensors, elevated LL-37 has been implicated in driving the type I interferon response seen in systemic lupus erythematosus and may be relevant in other autoimmune conditions (9). This is meaningful context for anyone with autoimmune history.
The body of LL-37 evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far. Long-term safety in humans has not been formally characterized.
All information on this site is for research and educational purposes only. The compounds discussed are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.